知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.014 seconds)

    BLOOD SAMPLE COLLECTION DEVICE WITH TIME STAMP AND SIMULTANEOUS ENVIRONMENTAL SAMPLE
    1.
    发明申请
    BLOOD SAMPLE COLLECTION DEVICE WITH TIME STAMP AND SIMULTANEOUS ENVIRONMENTAL SAMPLE 有权

    公开(公告)号：US20250009266A1

    公开(公告)日：2025-01-09

    申请号：US18891384

    申请日：2024-09-20

    Applicant: Nightingale Health Oyj

    Inventor： Brandon T. Johnson

    IPC: A61B5/15 ,  B01L3/00 ,  G16H10/40

    Abstract: A blood sample collection device includes a two-piece housing that encompasses a port at which a fingertip blood sample is collected. After the sample is taken, the two-piece housing is moved to a closed position to protect and optionally process the sample. A sample event detection circuit triggers a recording of a time when the sample was taken. The sample event detection circuit may determine when the housing is closed, or may detect the presence of blood in or near the sample port. The electronics may optionally record environmental conditions such as temperature or humidity, etc. at the time the sample is taken. The recorded data may then be used to enhance the value or accuracy of lab test, or for other purposes, such as inventory management.

    METHOD FOR DETERMINING WHETHER A SUBJECT IS AT RISK OF DEVELOPING A MENTAL AND/OR A BEHAVIOURAL DISORDER
    7.
    发明公开
    METHOD FOR DETERMINING WHETHER A SUBJECT IS AT RISK OF DEVELOPING A MENTAL AND/OR A BEHAVIOURAL DISORDER 审中-公开

    公开(公告)号：US20230393158A1

    公开(公告)日：2023-12-07

    申请号：US18271573

    申请日：2022-01-07

    Applicant: Nightingale Health Oyj

    Inventor： Peter Würtz ,  Heli Julkunen

    IPC: G01N33/92 ,  G01N33/68 ,  G01N24/08

    CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N24/08 ,  G01N2800/301 ,  G01N2800/50

    Abstract: A method for determining whether a subject is at risk of developing a mental disorder; wherein the method comprises determining in a biological sample obtained from the subject a quantitative value of at lease one bio-marker of the following in the biological sample: glycoprotein acetyls, albumin, a ratio of docosahexaenoic acid to total fatty acids, a ratio of linoleic acid to total fatty acids, a ratio of monounsaturated fatty acids and/or of oleic acid to total fatty acids, a ratio of omega-3 fatty acids to total fatty acids, a ratio of omega-6 fatty acids to total fatty acids, a ratio of saturated fatty acids to total fatty acids, fatty acid degree of unsaturation, docosahexaenoic acid, linoleic acid, monounsaturated fatty acids and/or oleic acid, omega-3 fatty acids, omega-6 fatty acids, saturated fatty acids, triglycerides in high-density lipoprotein (HDL), triglycerides in low-density lipoprotein (LDL), high-density lipoprotein (HDL) particle size, low-density lipoprotein (LDL) particle size, very-low-density lipoprotein (VLDL) particle size, acetate, citrate, glutamine, histidine; and comparing the quantitative value(s) of the at least one biomarker to a control sample or to a control value; wherein an increase or a decrease in the quantitative value(s) of the at least one biomarker, when compared to the control sample or to the control value, is/are indicative of the subject having an increased risk of developing a mental disorder; wherein the at least one biomarker comprises or is glycoprotein acetyls, and wherein the mental disorder is anxiety disorder and/or reaction to severe stress disorder.

Patent Agency Ranking